• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病视网膜病变中视网膜结构的重塑:炎症基因产物和细胞焦亡对眼生理和视觉功能的破坏

Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis.

作者信息

Homme Rubens P, Singh Mahavir, Majumder Avisek, George Akash K, Nair Kavya, Sandhu Harpal S, Tyagi Neetu, Lominadze David, Tyagi Suresh C

机构信息

Eye and Vision Science Laboratory, Department of Physiology, University of Louisville School of Medicine, Louisville, KY, United States.

Department of Physiology, University of Louisville School of Medicine, Louisville, KY, United States.

出版信息

Front Physiol. 2018 Sep 5;9:1268. doi: 10.3389/fphys.2018.01268. eCollection 2018.

DOI:10.3389/fphys.2018.01268
PMID:30233418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6134046/
Abstract

Diabetic patients suffer from a host of physiological abnormalities beyond just those of glucose metabolism. These abnormalities often lead to systemic inflammation via modulation of several inflammation-related genes, their respective gene products, homocysteine metabolism, and pyroptosis. The very nature of this homeostatic disruption re-sets the overall physiology of diabetics via upregulation of immune responses, enhanced retinal neovascularization, upregulation of epigenetic events, and disturbances in cells' redox regulatory system. This altered pathophysiological milieu can lead to the development of diabetic retinopathy (DR), a debilitating vision-threatening eye condition with microvascular complications. DR is the most prevalent cause of irreversible blindness in the working-age adults throughout the world as it can lead to severe structural and functional remodeling of the retina, decreasing vision and thus diminishing the quality of life. In this manuscript, we attempt to summarize recent developments and new insights to explore the very nature of this intertwined crosstalk between components of the immune system and their metabolic orchestrations to elucidate the pathophysiology of DR. Understanding the multifaceted nature of the cellular and molecular factors that are involved in DR could reveal new targets for effective diagnostics, therapeutics, prognostics, preventive tools, and finally strategies to combat the development and progression of DR in susceptible subjects.

摘要

糖尿病患者除了存在糖代谢异常外,还患有一系列生理异常。这些异常通常通过调节多个炎症相关基因、其各自的基因产物、同型半胱氨酸代谢和细胞焦亡,导致全身炎症。这种稳态破坏的本质通过上调免疫反应、增强视网膜新生血管形成、上调表观遗传事件以及扰乱细胞的氧化还原调节系统,重新设定了糖尿病患者的整体生理状态。这种改变的病理生理环境可导致糖尿病视网膜病变(DR)的发生,这是一种具有微血管并发症的、威胁视力的衰弱性眼病。DR是全世界工作年龄成年人不可逆失明的最常见原因,因为它可导致视网膜严重的结构和功能重塑,降低视力,从而降低生活质量。在本手稿中,我们试图总结近期的进展和新见解,以探索免疫系统各组成部分与其代谢调控之间这种相互交织的串扰的本质,从而阐明DR的病理生理学。了解参与DR的细胞和分子因素的多方面性质,可能揭示有效诊断、治疗、预后、预防工具的新靶点,并最终揭示对抗易感人群中DR发生和发展的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/73e3051929ff/fphys-09-01268-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/e8e5ba7f3784/fphys-09-01268-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/8f3453ce1b26/fphys-09-01268-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/24c62dcabb54/fphys-09-01268-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/e32ebec994bb/fphys-09-01268-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/73e3051929ff/fphys-09-01268-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/e8e5ba7f3784/fphys-09-01268-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/8f3453ce1b26/fphys-09-01268-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/24c62dcabb54/fphys-09-01268-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/e32ebec994bb/fphys-09-01268-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/868d/6134046/73e3051929ff/fphys-09-01268-g005.jpg

相似文献

1
Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis.糖尿病视网膜病变中视网膜结构的重塑:炎症基因产物和细胞焦亡对眼生理和视觉功能的破坏
Front Physiol. 2018 Sep 5;9:1268. doi: 10.3389/fphys.2018.01268. eCollection 2018.
2
Elucidating glial responses to products of diabetes-associated systemic dyshomeostasis.阐明与糖尿病相关的全身稳态失调产物引起的神经胶质反应。
Prog Retin Eye Res. 2023 May;94:101151. doi: 10.1016/j.preteyeres.2022.101151. Epub 2023 Apr 5.
3
Targeting the NLRP3 inflammasome in diabetic retinopathy: From pathogenesis to therapeutic strategies.靶向糖尿病性视网膜病变中的 NLRP3 炎性小体:从发病机制到治疗策略。
Biochem Pharmacol. 2023 Jun;212:115569. doi: 10.1016/j.bcp.2023.115569. Epub 2023 Apr 25.
4
The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in diabetic retinopathy.NLRP3 炎性小体/细胞焦亡激活的机制及其在糖尿病视网膜病变中的作用。
Front Immunol. 2023 Apr 25;14:1151185. doi: 10.3389/fimmu.2023.1151185. eCollection 2023.
5
Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy.糖尿病视网膜病变病理变化的机制性见解:对糖尿病视网膜病变靶向治疗的启示
Am J Pathol. 2017 Jan;187(1):9-19. doi: 10.1016/j.ajpath.2016.08.022. Epub 2016 Nov 12.
6
Reduction of Glut1 in the Neural Retina But Not the RPE Alleviates Polyol Accumulation and Normalizes Early Characteristics of Diabetic Retinopathy.神经视网膜中 Glut1 的减少而非 RPE 可减轻多元醇的积累并使糖尿病视网膜病变的早期特征正常化。
J Neurosci. 2021 Apr 7;41(14):3275-3299. doi: 10.1523/JNEUROSCI.2010-20.2021. Epub 2021 Feb 23.
7
Molecular investigation of candidate genes for pyroptosis-induced inflammation in diabetic retinopathy.糖尿病性视网膜病变中细胞焦亡诱导炎症候选基因的分子研究。
Front Endocrinol (Lausanne). 2022 Jul 25;13:918605. doi: 10.3389/fendo.2022.918605. eCollection 2022.
8
MicroRNA-150 (miR-150) and Diabetic Retinopathy: Is miR-150 Only a Biomarker or Does It Contribute to Disease Progression?微小 RNA-150(miR-150)与糖尿病视网膜病变:miR-150 仅是生物标志物还是会促进疾病进展?
Int J Mol Sci. 2022 Oct 11;23(20):12099. doi: 10.3390/ijms232012099.
9
Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by modulating miR-342-3p targeting of CASP1 in diabetic retinopathy.长链非编码 RNA MIAT 通过调节 miR-342-3p 靶向 CASP1 调节糖尿病视网膜病变中原发性人视网膜周细胞细胞焦亡。
Exp Eye Res. 2021 Jan;202:108300. doi: 10.1016/j.exer.2020.108300. Epub 2020 Oct 13.
10
The Role of Inflammation in Diabetic Retinopathy.炎症在糖尿病视网膜病变中的作用。
Front Immunol. 2020 Nov 6;11:583687. doi: 10.3389/fimmu.2020.583687. eCollection 2020.

引用本文的文献

1
Role of the NLRP3 inflammasome in diabetes and its complications (Review).NLRP3炎性小体在糖尿病及其并发症中的作用(综述)
Mol Med Rep. 2025 Nov;32(5). doi: 10.3892/mmr.2025.13657. Epub 2025 Aug 24.
2
Identification of PANoptosis-related genes as biomarkers in ischemic stroke.鉴定PANoptosis相关基因作为缺血性中风的生物标志物
Front Neurol. 2025 Jul 25;16:1560514. doi: 10.3389/fneur.2025.1560514. eCollection 2025.
3
Vitrectomy for Epiretinal Membrane Peeling in Patients with Diabetic Retinopathy-Functional and Morphological Outcome.

本文引用的文献

1
The Systemic Safety of Ranibizumab in Patients 85 Years and Older with Neovascular Age-Related Macular Degeneration.雷珠单抗在85岁及以上新生血管性年龄相关性黄斑变性患者中的全身安全性。
Ophthalmol Retina. 2018 Jul;2(7):667-675. doi: 10.1016/j.oret.2018.01.010. Epub 2018 Feb 27.
2
Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor.一名糖尿病患者在使用最小剂量钠-葡萄糖协同转运蛋白2抑制剂后糖尿病性黄斑水肿的恢复情况
Am J Case Rep. 2018 Apr 19;19:462-466. doi: 10.12659/ajcr.909708.
3
Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema.
糖尿病视网膜病变患者视网膜前膜剥除的玻璃体切除术——功能和形态学结果
J Clin Med. 2025 Jul 18;14(14):5128. doi: 10.3390/jcm14145128.
4
Thermosensitive hydrogel composite with si-Cx43 nanoparticles and anti-VEGF agent for synergistic treatment of diabetic retinopathy.含si-Cx43纳米颗粒和抗血管内皮生长因子药物的热敏水凝胶复合物用于糖尿病视网膜病变的协同治疗
Mater Today Bio. 2025 May 29;33:101917. doi: 10.1016/j.mtbio.2025.101917. eCollection 2025 Aug.
5
NLRP3 inflammasomes pathway: a key target for Metformin.NLRP3炎性小体通路:二甲双胍的关键靶点。
Inflammopharmacology. 2025 Apr;33(4):1729-1760. doi: 10.1007/s10787-025-01702-4. Epub 2025 Mar 5.
6
Inhibition of the polyol pathway by extract: plausible implications for diabetic retinopathy treatment.提取物对多元醇途径的抑制作用:对糖尿病视网膜病变治疗的潜在意义。
Front Pharmacol. 2024 Dec 23;15:1513967. doi: 10.3389/fphar.2024.1513967. eCollection 2024.
7
PSAT1 is upregulated by METTL3 to attenuate high glucose-induced retinal pigment epithelial cell apoptosis and oxidative stress.PSAT1 通过 METTL3 的上调来减轻高糖诱导的视网膜色素上皮细胞凋亡和氧化应激。
Diagn Pathol. 2024 Oct 15;19(1):138. doi: 10.1186/s13000-024-01556-4.
8
Deciphering the Potentials of Cardamom in Cancer Prevention and Therapy: From Kitchen to Clinic.解析小豆蔻在癌症预防和治疗中的潜力:从厨房到临床。
Biomolecules. 2024 Sep 18;14(9):1166. doi: 10.3390/biom14091166.
9
Differences in macular thickness associated with peripheral retinal vessel whitening in diabetic patients.糖尿病患者周边视网膜血管变白与黄斑厚度的差异。
Sci Rep. 2024 Aug 27;14(1):19881. doi: 10.1038/s41598-024-68839-0.
10
Peptain-1 blocks ischemia/reperfusion-induced retinal capillary degeneration in mice.胃蛋白酶-1可阻止小鼠缺血/再灌注诱导的视网膜毛细血管变性。
Front Cell Neurosci. 2024 Aug 1;18:1441924. doi: 10.3389/fncel.2024.1441924. eCollection 2024.
基于糖尿病性黄斑水肿抗血管内皮生长因子治疗早期反应的视觉预后
Ophthalmologica. 2018;239(2-3):94-102. doi: 10.1159/000481711. Epub 2018 Jan 9.
4
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Subgroup Analyses From the VIEW Trials.玻璃体内注射阿柏西普和雷珠单抗治疗亚洲新生血管性年龄相关性黄斑变性的疗效和安全性:VIEW 试验的亚组分析。
Retina. 2019 Mar;39(3):537-547. doi: 10.1097/IAE.0000000000001986.
5
Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation.非诺贝特通过调节 Nrf2 信号通路和 NLRP3 炎性小体的激活来改善糖尿病视网膜病变。
Mol Cell Biochem. 2018 Aug;445(1-2):105-115. doi: 10.1007/s11010-017-3256-x. Epub 2017 Dec 21.
6
Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.丹麦国家指南指导下,566 例糖尿病黄斑水肿患者接受玻璃体腔抗血管内皮生长因子治疗:2-4 年视力和视网膜厚度随访结果。
Acta Ophthalmol. 2018 May;96(3):267-278. doi: 10.1111/aos.13638. Epub 2017 Dec 14.
7
Macrovascular Complications in Patients with Diabetes and Prediabetes.糖尿病和糖尿病前期患者的大血管并发症。
Biomed Res Int. 2017;2017:7839101. doi: 10.1155/2017/7839101. Epub 2017 Nov 7.
8
Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.与雷珠单抗相比,阿柏西普治疗患者的注射频率和医疗费用:来自瑞士的新实际证据。
BMC Ophthalmol. 2017 Dec 4;17(1):234. doi: 10.1186/s12886-017-0617-x.
9
AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.雷珠单抗眼内注射后应用阿柏西普治疗渗出型年龄相关性黄斑变性:ARI2 研究。
Retina. 2018 Dec;38(12):2285-2292. doi: 10.1097/IAE.0000000000001928.
10
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.糖尿病微血管病变:内分泌学会科学声明
J Clin Endocrinol Metab. 2017 Dec 1;102(12):4343-4410. doi: 10.1210/jc.2017-01922.